{"id":"placebo-capsules-letrozole-anastrozole-tamoxifen","safety":{"commonSideEffects":[{"rate":"50-80%","effect":"Hot flashes"},{"rate":"30-50%","effect":"Vaginal dryness"},{"rate":"20-40%","effect":"Musculoskeletal pain"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Aromatase inhibitors like Letrozole and Anastrozole work by inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens. By blocking this enzyme, they reduce estrogen levels in the body. Tamoxifen, on the other hand, binds to estrogen receptors in breast tissue, blocking the action of estrogen and thereby inhibiting the growth of estrogen receptor-positive breast cancer cells.","oneSentence":"Letrozole and Anastrozole are aromatase inhibitors, which block the production of estrogen in the body. Tamoxifen is a selective estrogen receptor modulator (SERM), which blocks estrogen receptors in breast tissue.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:43.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women"},{"name":"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT05780567","phase":"PHASE3","title":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-03-30","conditions":"Breast Cancer","enrollment":1946}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo capsules, Letrozole, Anastrozole, Tamoxifen","genericName":"Placebo capsules, Letrozole, Anastrozole, Tamoxifen","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Letrozole and Anastrozole are aromatase inhibitors, which block the production of estrogen in the body. Tamoxifen is a selective estrogen receptor modulator (SERM), which blocks estrogen receptors in breast tissue. Used for Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women, Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}